Hemostatic changes after COVID-19 vaccination in patients with hematologic malignancy diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20211109005

Enrollment

400

Registered

2021-11-09

Start date

2021-07-16

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer patients are considered to be at higher risk of thrombosis than the normal population. As previously reported, thromboembolic complications are five times more common among cancer patients than the normal population, with up to 10-15% during the incurable period. Patients with hematologic malignancies also have an increased risk of thromboembolic complications. Hemostatic changes after COVID-19 vaccination in patients with hematologic malignancy diseases

Interventions

The patients 18 years and older, known to have Leukemia and lymphoma, receive the first dose of COVID-19 vaccine (unlimited brands) and never had a history of covid-19 infection.

Other

The patients 18 years and older, known to have Leukemia and lymphoma.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.The patient 18 years and older and diagnosis leukemia and lymphoma under treatment or is undergoing follow-up 2.the patient receive the first dose of COVID-19 vaccinate not limited to the brand name and has not been infected with covid-19 before.

Exclusion criteria

Exclusion criteria: 1 .Pregnant woman. 2. History of venous thromboembolism in the past 3 months. 3. History of receiving other vaccines within 28 days before vaccination against COVID-19.

Design outcomes

Primary

Measure	Time frame
Changes of D-dimer values before and after vaccination against COVID-19 in all patients with leukemia and lymphoma. First visit and 3 weekly D-dimer values	—

Secondary

Measure	Time frame
thrombin generation assay before and after vaccination against COVID-19 in all patients with leukemia and lymphoma. First visit and 3 weekly Thrombin generation assay values,Anti pf4 values before and after vaccination against COVID-19 in all patients with leukemia and lymphoma. First visit and 3 weekly Anti pf4 values	—

Countries

Thailand

Contacts

Public ContactWeerapat Owattanapanich

Division of Hematology,Faculty of Medicine Siriraj Hospital,Mahidol University.

weerapato36733@gmail.com0891081963

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026